Skip to content

Neogene Therapeutics

Neogene Therapeutics

Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers. Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.  Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications. Expertise: T cell therapy Interested in joining? Please visit our career page.
Neogene Therapeutics
Contactpersoon
Martine Serné
Adres
Science Park 106 1098 XG Amsterdam Matrix SEVEN
Telefoonnummer
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers. Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.  Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications. Expertise: T cell therapy Interested in joining? Please visit our career page.
Contactpersoon
Martine Serné
Adres
Science Park 106 1098 XG Amsterdam Matrix SEVEN

Stay In Touch.

Coming soon

Our website is currently being translated to English. This website will be soon available in English.